Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Sep 2018: Trial registered, NCT03661307
  2. 31 Oct 2018: Trial started, NCT03661307

The trials

NCT03661307: Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

State
Under way
Phase
Phase 1 and Phase 2
People
129 taking part
Started
31 Oct 2018
Primary completion
1 Jan 2028
Arms
Treatment (decitabine, quizartinib, venetoclax)
Results
None posted
  1. 7 Sep 2018: Trial registered
  2. 31 Oct 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.